CML is a rare malignant blood disease associated with a genetic mutation. It was almost unrequited before the emergence of modern drugs, but thanks to the inhibitors of Tirosinkinaz inhibitors, patients have been living for decades today. However, even modern drugs do not work in everyone: approximately one quarter of patients develop resistance to treatment or serious side effects occur.
New drug Vamotinib is for patients – those who develop resistance or intolerance to previous treatment. Clinical studies have shown that this is effective and has an advanced safety profile, especially in terms of cardiovascular complications.
The drug is at the last stage of the research and may enter the market in the near future.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
